Download or read book Use of Left Ventricular Assist Devices As Destination Therapy in End Stage Congestive Heart Failure a Systematic Review written by U. S. Department of Veterans Affairs and published by Createspace Independent Pub. This book was released on 2013-05-22 with total page 48 pages. Available in PDF, EPUB and Kindle. Book excerpt: Several common chronic conditions such as atherosclerotic heart disease and hypertension as well as other diseases can result in heart failure, a reduced ability of the heart to pump blood and maintain normal bodily functions. More than 100,000 people in the U.S. with progressive heart failure are refractory to available treatments and have high rates of hospitalization and mortality and a poor quality of life due to limited physical and social activities and psychological stress. Heart transplantation is currently the preferred treatment for end-stage heart failure. Unfortunately, the supply of donor hearts is far less than needed and many patients do not meet the criteria for heart transplantation primarily due to old age and comorbidities such as diabetes with damage to vital organs, pulmonary hypertension, renal insufficiency, malignancies and morbid obesity. Implantable mechanical pumps that assist the circulation of blood by one or both ventricles of the heart have evolved over several decades. Typically blood flows from the native left ventricle of the heart into the surgically implanted assist device and is pumped out into the aorta via an implanted conduit. Currently, long-term implantable left ventricular assist devices require an external source of power and control module. Surgical placement of a left ventricular assist device is increasingly done as a last resort for patients with refractory heart failure who are not eligible for heart transplantation, so called destination therapy. Some patients may improve after they receive a ventricular assist device as destination therapy and become eligible for heart transplantation even though this was not the initial therapeutic goal. A limited number may recover enough heart function to not need a heart transplant or mechanical assist device. Although survival with a newer generation continuous flow ventricular assist device is approaching that of a heart transplant, long-term use of the device by patients who are eligible for a heart transplant is not currently accepted practice. Conversely, many patients that receive a ventricular assist device as a bridge to transplant use the device for increasingly prolonged periods while waiting for a donated heart and some may become ineligible for a heart transplant. The purpose of this report is to review the scientific evidence for use of ventricular assist devices as destination therapy for patients with severe, refractory heart failure who are not eligible for heart transplantation at the time the device is implanted. Although many patients receive the same types of ventricular assist devices as a bridge to heart transplantation or recovery, the characteristics, hence risk profiles, of patients receiving bridge therapy are different from patients selected to receive a device as permanent destination therapy. Furthermore many bridged patients do receive a heart transplant that alters patient outcomes. This review focused on evidence about patient outcomes, patient selection and cost effectiveness of ventricular assist devices specifically intended as destination therapy. The primary goals of destination therapy are to: prolong survival, improve daily function and health-related quality of life, minimize harms including infection, major bleeding episodes, thromboembolic events including strokes and device malfunction or failure especially those that require hospital care. The key questions were: #1. How does use of an FDA-approved, current generation LVAD as destination therapy (i.e., the HeartMate II left ventricular assist device) effect patient outcomes? #2. What patient or site characteristics have been associated with patient benefits or harms when the FDA-approved, current generation LVAD is used as destination therapy? #3. What is the range of cost-effectiveness estimates of using the FDA-approved, current generation LVAD as destination therapy in end-stage heart failure and what explains variation in these estimates?

Download or read book Use of Left Ventricular Assist Devices as Destination Therapy in End stage Congestive Heart Failure written by Thomas S. Rector and published by . This book was released on 2012 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Heart failure is defined as reduced ability of the heart to pump blood and maintain normal bodily function. Heart transplantation is currently the preferred treatment for end-stage heart failure but the supply of donor hearts is insufficient to meet the need and many patients are not eligible for transplantation due to age or comorbid conditions. Implantable mechanical pumps can assist the circulation of blood by the ventricles. Left ventricular assist devices (LVADs) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients awaiting transplant (a bridge to transplant) and as a last resort in patients with refractory heart failure who are not eligible for a heart transplant (destination therapy). In January 2010, the first newer generation, rotary continuous flow ventricular assist device (HeartMate II) was approved by the FDA for destination therapy. Eligibility criteria are essentially the same as those used to select patients for the pivotal clinical trial that included patients with shortness of breath and/or fatigue at rest or during minimal exertion despite treatment with optimal therapy for heart failure associated with a low ejection fraction (

Download or read book Use of Left Ventricular Assist Devices as Destination Therapy in End stage Congestive Heart Failure written by Thomas S. Rector and published by . This book was released on 2012 with total page 41 pages. Available in PDF, EPUB and Kindle. Book excerpt: Heart failure is defined as reduced ability of the heart to pump blood and maintain normal bodily function. Heart transplantation is currently the preferred treatment for end-stage heart failure but the supply of donor hearts is insufficient to meet the need and many patients are not eligible for transplantation due to age or comorbid conditions. Implantable mechanical pumps can assist the circulation of blood by the ventricles. Left ventricular assist devices (LVADs) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients awaiting transplant (a bridge to transplant) and as a last resort in patients with refractory heart failure who are not eligible for a heart transplant (destination therapy). In January 2010, the first newer generation, rotary continuous flow ventricular assist device (HeartMate II) was approved by the FDA for destination therapy. Eligibility criteria are essentially the same as those used to select patients for the pivotal clinical trial that included patients with shortness of breath and/or fatigue at rest or during minimal exertion despite treatment with optimal therapy for heart failure associated with a low ejection fraction (

Download or read book Left Ventricular Assist Devices An Issue of Cardiology Clinics E Book written by John A. Elefteriades and published by Elsevier Health Sciences. This book was released on 2011-11-29 with total page 188 pages. Available in PDF, EPUB and Kindle. Book excerpt: A left ventricular assist device (LVAD) is a surgically implanted pump that helps the left ventricle pump blood to the rest of the body. The purpose of this issue is to let cardiologists know about the latest devices, their complications, and the clinical situations in which they are most beneficial.

Download or read book Ventricular Assist Devices in Advanced Stage Heart Failure written by Shunei Kyo and published by Springer Science & Business Media. This book was released on 2013-11-25 with total page 154 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book focuses on how ventricular assist devices (VADs) can help provide destination therapy for patients with terminal heart failure, one of the most serious diseases in the world today because of the tremendous number of patients, the high mortality rate, and the cost of care. One means of providing cardiological support for patients suffering from heart failure is with VADs, and more than 10,000 patients worldwide have now been implanted with these devices. Half of them already have lived more than one year, and 2,000 patients more than two years, after surgery. This improved survival means that we have reached a point where VADs can be used for destination therapy, not just for bridge-to-recovery or bridge-to-transplant. In view of the increasing number of patients with advanced-stage heart failure and the availability and longevity of transplanted hearts, VADs can solve many problems. In addition to providing information about the devices themselves, this book includes vital guidelines on long-term management and support of VAD-implanted patients’ everyday lives.

Download or read book Left Ventricular Assist Device LVAD as Destination Therapy for Patients with Endstage Heartfailure written by Vigdis Lauvrak and published by . This book was released on 2013 with total page 5 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Norwegian National Council for Priority Setting in the Health Care recommended in 2008 that left ventricular assist device (LVAD) should be offered to patients only for a limited period of time, for example while awaiting heart transplantation. This recommendation may be reconsidered. We have assessed LVAD as destination therapy. In 2008, there was one randomized controlled trial (RCT) comparing first-generation LVAD with optimal medical treatment. A literature search performed in June 2013 provided an RCT from 2009 that compared second-generation LVAD with first-generation LVAD, a few recent prospective case series, registry data and two relevant international cost-effectiveness analyses. Our main conclusions are: 1. Compared with optimal medical therapy LVAD can provide extended life time and improved quality of life for selected patients with end-stage heart failure. The magnitude of the clinical effect is uncertain. 2. There are no studies comparing LVAD with heart transplantation. 3. The most common complications associated with LVAD are bleeding, infections, need for pump replacement, stroke and right ventricular heart failure. These complications are the major cause of death the first two years following pump insertion. 4. The costs of LVAD have been reduced since 2008, but they are still high. International cost-effectiveness analyses are associated with uncertainty. A Norwegian cost-effectiveness analysis has not been performed. 5. Both to offer and not to offer LVAD as destination therapy is ethically challenging.

Download or read book Decisional Considerations in Left Ventricular Assist Device for Destination Therapy written by Megan Laila Morrison and published by . This book was released on 2016 with total page 93 pages. Available in PDF, EPUB and Kindle. Book excerpt: End-stage heart failure is a growing problem in the United States as well as world-wide. The definitive treatment in heart failure that is refractory to medical treatment is a heart transplant. But there are a limited numbers of hearts available for transplant and a growing number of patients in need. There has recently been tremendous development in the area of mechanical circulatory support. One of these developments is the left ventricular assist device (LVAD). The LVAD is a pump that assists the failing left ventricle of the heart. The LVAD has proven to increase survival and improve symptoms of end-stage heart failure. Initially the LVAD was used to support patients with heart failure to survive to either recovery or heart transplant, thus termed a bridge therapy. But eventually these devices would be implanted without the intent of heart transplant or recovery, becoming known as destination therapy. A third category of LVAD designation is called bridge to candidacy. In this category patients undergo the implantation of the LVAD and then are later determined whether they are appropriate for heart transplant. For all patients and families who undertake LVAD therapy, there are risks, uncertainty, and benefits of the treatment. All categories of patients are making high-stakes decisions for their care while living under the threat of a life threatening condition. As is often the case in highly technological devices that prolong and sustain life, LVADs come with very serious and complex ethical challenges as well as psychosocial demands on patients and families. The first paper in this manuscript addresses the ethical principle of prospective autonomy. The paper uses Walker and Avant’s method of concept analysis to come to an operational definition of the concept of prospective autonomy. The definition achieved is: Exerting current values, life experiences, and perspective to decide the course of one’s future. The defining attributes of the concept are identified as: oriented to the future and events that have not yet happened, independence in that the individual is choosing their course, competency in that the individual meets a threshold for ability to make a rational and prudent choice, authenticity in that it must reflect the individual’s true self, knowledge that the person must have the pertinent information that is available, and lastly, self-determination. The second paper describes original research investigating the process of decision-making in LVAD for destination therapy. The study was conducted with 11 participants with LVADs for destination therapy. The research found that the core process in decision-making was “no choice”. This core process was sub-divided into two supporting processes: (a) being in a system of care and (b) having already invested so much in the LVAD. Additional interacting process themes were: (a) personal bias, (b) reacting, (c) perceiving what clinicians thought the participant should do, (d) unclear goals and hopes, (e) isolation, and (f) severely constrained planning for the future. The third paper is a secondary analysis from the above mentioned study on decision-making. This manuscript was generated from the unexpected finding of grief around the loss of hope for heart transplant in the participants. The themes identified in this analysis were: (a) taking it in, (b) heart transplant is not perfect, (c) jumping through hoops, (d) mistrust, (e) thinking about the hypothetical, and (f) hope.

Download or read book Rotary Blood Pumps written by Hikaru Matsuda and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 153 pages. Available in PDF, EPUB and Kindle. Book excerpt: Rotary blood pumps increasingly are being used in open heart surgery and in assisted circulation for patients with heart disease. These rotary devices include vortex (centrifugal) and axial pumps, which can be utilized in conditions where the use of conventional pulsatile pumps would entail problems of cost and size. Rapid progress is now being made in developing new devices for controlling blood flow within the heart and great vessels as well as extracorporeally for use in coronary and intensive care units and, in the future, for long-term use. This book provides information on the physiology of nonpulsatile circulation, the development of rotary pump engineering, and the clinical application of rotary blood pumps. It also presents an overview of future developments in this important field.

Download or read book Mechanical Circulatory Support in End Stage Heart Failure written by Andrea Montalto and published by Springer. This book was released on 2017-07-14 with total page 601 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a detailed practical guide to the use of ventricular assist devices and total artificial hearts to provide mechanical circulatory support (MCS) in patients with end-stage heart failure. It explains why MCS may be indicated, which patients require MCS, when and how to implant ventricular assist devices or a total artificial heart, and how to avoid potential complications of MCS. Management throughout the period of care is described, from preimplantation to follow-up, and both typical and atypical cases are discussed. The text features numerous helpful tips and tricks relating to surgical and nonsurgical management and is supported by a wealth of high-quality illustrations that document the preoperative evaluation and implantation techniques. Heart transplantation remains the gold standard for the treatment of patients suffering from end-stage heart failure, but the shortage of donors has led to an increase in the use of MCS. This book will assist all physicians, and especially cardiologists and anesthesiologists, who are involved in the care of these patients.

Download or read book Left Ventricular Assist Devices for Destination Therapy written by Health Quality Ontario and published by . This book was released on 2016 with total page 60 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Recent Advances in the Field of Ventricular Assist Devices written by Kazuo Komamura and published by BoD – Books on Demand. This book was released on 2013-05-08 with total page 106 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recent Advances in the Field of Ventricular Assist Devices covers recent various advances and developments relating to ventricular assist devices and their diverse complications. Firstly, we overview recent technical advances as well as current indications, clinical outcomes, and countermeasures against complications, and furthermore, the latest techniques to identify clinical effectiveness at the patient’s bedside. Secondly, we elucidate the current status of countermeasures against gastrointestinal bleeding, and current research on allosensitization during the usage of continuous flow pump. Finally, we explore the possibility of a new adjunct therapy in combination with ventricular assist devices. We hope that this book will provide valuable and up-to-date information on research and clinical use of ventricular assist devices.

Download or read book Acoustic and afterload evaluation of left ventricular assist devices written by Per Sundbom and published by Linköping University Electronic Press. This book was released on 2019-11-12 with total page 86 pages. Available in PDF, EPUB and Kindle. Book excerpt: Background: Heart Failure is a serious condition with consequences not only for the individual patient but also for the society with a 5-year mortality rate of 45-60%, and a substantial economic burden. The estimated prevalence in Sweden is 2.2% and the age adjusted prevalence increases with higher age. The fundamental treatment for heart failure is pharmaceutical in combination with life-style changes, and physiotherapy. For patients with advanced heart failure, the use of long-term circulatory support can be an option as a bridge to transplantation, or as destination therapy. However, this treatment entails a risk of multiple adverse events. The incidence of pump thrombosis increased as a clinical problem in 2012 and the need for diagnostic methods were desired. The aim of this thesis was to develop and to evaluate the use of a mock loop circuit to study the acoustics of left ventricular assist devices, to evaluate different recording devices and to study the effect of afterload on pump function. Methods: Two different mock loops, with the possibility to insert artificial thrombus and to adjust preload and afterload were created to facilitate recording of the left ventricular assist devices. An iPhone/iPodTM was used as recording device since remote monitoring is desirable. The sounds from HeartMate IITM during different conditions were studied. The iPhone/iPod was evaluated in comparison to dedicated recording equipment, and the mock loop recordings to clinical situation. The sound from HeartMate 3TM was studied, compared between in vivo and in vitro recordings, and the use of an electronic stethoscope was evaluated. The impact of afterload on left ventricular assist devices was studied in a mock loop circuit with different changes in preload and afterload. Results: Mock loop circuit is a promising method to safely change the surrounding conditions as the pump is working. The sound from both HeartMate IITM and HeartMate 3TM can be recorded and analyzed in frequency and time domain. When inserting artificial thrombus in a HeartMate IITM the frequency spectrum is altered. The use of dedicated recording devices is superior to both electronic stethoscope and iPhone/iPodTM, but these handheld devices can be used in clinical settings. The recordings from mock loop circuit and patients appear similar for both HeartMate IITM and HeartMate 3TM. The flow of the devices is affected by the afterload. The HeartMate 3TM is more resistant to increased clot analogs within the pump. For both pumps, best efficacy is seen for clean circuits. The flow rate from the monitor might be misleading since the measured flow rate and the flow rate from monitor can differ due to surrounding conditions. The estimated flow might be adjusted by fitting a parabolic curve. Conclusion: The use of mock loop circuit to study both flow and sound under different conditions is valid. It is possible to record and study the sound from both HeartMate IITM and HeartMate 3TM. The sound holds information of pump function and appears similar in vivo and in vitro. All recording devices can be used, but dedicated equipment is superior to the more handheld devices, although these might have a function as a screening device. The flow measurement on the monitor might not be valid and optimization of fluid status and afterload can further increase pump efficiency.

Download or read book New Aspects of Ventricular Assist Devices written by Guillermo Reyes and published by BoD – Books on Demand. This book was released on 2011-08-29 with total page 146 pages. Available in PDF, EPUB and Kindle. Book excerpt: Ventricular assist device has become one of the standard therapies for the support and the management of the failing heart. Updating our knowledge about these devices is mandatory in order to improve patient outcomes. In this book we can read the efforts made by many physicians concerned with the treatment of heart failure with mechanical devices. We all hope that the information compiled by experts in ventricle assist devices in this book will help us all to do better our main task - heal patients.

Download or read book Core Topics in Cardiothoracic Critical Care written by Kamen Valchanov and published by Cambridge University Press. This book was released on 2018-07-05 with total page 541 pages. Available in PDF, EPUB and Kindle. Book excerpt: Most patients with critical cardiac or thoracic conditions will at some stage pass through the cardiothoracic critical care unit. Critical care presents more complex clinical data than any other area of medicine. The new edition of Core Topics in Cardiothoracic Critical Care focuses on the latest practise in the management of patients in cardiothoracic intensive care. The practice of cardiothoracic critical care medicine is constantly evolving, and this new edition reflects the modernized learning styles for trainees. Each chapter includes key learning points as well as sample multiple choice questions and answers to assist in exam preparation. This edition also features updated chapters on ECMO, perioperative management of patients undergoing emergency cardiothoracic surgery, and advanced modes of organ support for patients. This text provides key knowledge in a concise and accessible manner for trainees, clinicians and consultants from specialities and disciplines such as cardiology and anaesthesia, and nursing and physiotherapy.

Download or read book The Clinical and Cost effectiveness of Left Ventricular Assist Devices for End stage Heart Failure written by A. J. Clegg and published by . This book was released on 2005 with total page 148 pages. Available in PDF, EPUB and Kindle. Book excerpt: Objective "to assess the clinical and cost effectiveness of left ventricular assist devices (LVADs) as a bridge to heart transplantation (BTT), as a bridge to myocardial recovery (BTR) or as a long-term chronic support for people with end-stage heart failure (ESHF)." p.iii.

Download or read book Advanced Concepts in Endocarditis written by Michael S. Firstenberg and published by . This book was released on 2018-09-12 with total page 201 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Essential Clinical Anesthesia written by Charles Vacanti and published by Cambridge University Press. This book was released on 2011-07-11 with total page 1191 pages. Available in PDF, EPUB and Kindle. Book excerpt: The clinical practice of anesthesia has undergone many advances in the past few years, making this the perfect time for a new state-of-the-art anesthesia textbook for practitioners and trainees. The goal of this book is to provide a modern, clinically focused textbook giving rapid access to comprehensive, succinct knowledge from experts in the field. All clinical topics of relevance to anesthesiology are organized into 29 sections consisting of more than 180 chapters. The print version contains 166 chapters that cover all of the essential clinical topics, while an additional 17 chapters on subjects of interest to the more advanced practitioner can be freely accessed at www.cambridge.org/vacanti. Newer techniques such as ultrasound nerve blocks, robotic surgery and transesophageal echocardiography are included, and numerous illustrations and tables assist the reader in rapidly assimilating key information. This authoritative text is edited by distinguished Harvard Medical School faculty, with contributors from many of the leading academic anesthesiology departments in the United States and an introduction from Dr S. R. Mallampati. This book is your essential companion when preparing for board review and recertification exams and in your daily clinical practice.